Inflammatory bowel disease-attributable costs and cost-effective strategies in the United States: a review.
The United States spends more for healthcare than any other country in the world. With the rising prevalence of both Crohn's disease and ulcerative colitis, inflammatory bowel disease (IBD) represents the leading chronic gastrointestinal disease with increasing healthcare expenditures in the US. IBD costs have shifted from inpatient to outpatient care since the introduction of biologic therapies as the standard of care. Gastroenterologists need to be aware of the national cost burden of IBD and clinical practices that optimize cost-efficiency. This investigation offers a systematic review of the economics of IBD and evidence-based strategies for cost-effective management.
Pediatric Gastroenterology, Hepatology, and Nutrition, Lucile Packard Children's Hospital, Stanford University Medical Center, Stanford, California, CA, USA. ktpark@stanford.edu
K T
KT
Park
Dorsey
D
Bass
D003362:Cost-Benefit Analysis; D017048:Health Care Costs; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000191:economics* / Q000628:therapy; D014481:United States